(Q35771300)

English

A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer

scientific article published on 27 July 2011

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

phase II clinical trial

0 references

estrogen-receptor positive breast cancer

0 references

1 reference

based on heuristic

inferred from title

5

object named as

Heidi Weiss

0 references

Suleiman Massarweh

1

object named as

Suleiman Massarweh

0 references

6

object named as

Anna Tsimelzon

0 references

author name string

Yee L Tham

2

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Jian Huang

3

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Krystal Sexton

4

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Amanda Beyer

7

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Mothaffar Rimawi

8

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Wei Yen Cai

9

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Susan Hilsenbeck

10

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Suzanne Fuqua

11

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Richard Elledge

12

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

language of work or name

0 references

publication date

27 July 2011

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

129

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

819-827

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477822

12 July 2018

Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477822

12 July 2018

Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477822

12 July 2018

Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477822

12 July 2018

Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477822

12 July 2018

Cyclin D1 is necessary for tamoxifen-induced cell cycle progression in human breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477822

12 July 2018

Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477822

12 July 2018

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477822

12 July 2018

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477822

12 July 2018

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477822

12 July 2018

Using the gene ontology for microarray data mining: a comparison of methods and application to age effects in human prefrontal cortex

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477822

12 July 2018

Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477822

12 July 2018

Neoadjuvant endocrine therapy for breast cancer: medical perspectives

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477822

12 July 2018

Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477822

12 July 2018

Regulation of the functional interaction between cyclin D1 and the estrogen receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477822

12 July 2018

Molecular markers for predicting response to tamoxifen in breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477822

12 July 2018

Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477822

12 July 2018

Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477822

12 July 2018

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1679-8

21 January 2018

Insights into the place of fulvestrant for the treatment of advanced endocrine responsive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1679-8

21 January 2018

EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1679-8

21 January 2018

Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1679-8

21 January 2018

Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1679-8

21 January 2018

Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1679-8

21 January 2018

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1679-8

21 January 2018

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4477822

25 September 2018

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21792626

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21792626

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor characteristics and clinical outcome of elderly women with breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21792626

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21792626

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM

1 reference

https://pubmed.ncbi.nlm.nih.gov/21792626

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neoadjuvant chemotherapy in young breast cancer patients: correlation between response and relapse?

1 reference

https://pubmed.ncbi.nlm.nih.gov/21792626

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21792626

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21792626

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21792626

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21792626

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10549-011-1679-8

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35771300&oldid=2197720252"